Single pill combinations (SPC) represent an innovation in the daily lives of patients with chronic diseases. SPCs are medications that combine several treatments into a single pill, which makes it easier for patients to take. Likewise, prescribing treatments is simpler, fostering the patient’s therapeutic adherence. SPCs are a significant advance that allows patients to take better control of their disease, thereby preventing potential complications.
Very often, patients with chronic illnesses face the need to take multiple treatments. Over time, and depending on disease progression, the number of pills can increase. This makes treatment even more complex and may be discouraging for many patients. This is especially true for patients who are being monitored for several chronic diseases. For example, 49% of people with hypertension have dyslipidemia, while 29% have type 2 diabetes1. This is why adhering to one’s treatment can be tough!
Innovative combinations of molecules and new dosages
The latest advances in drug formulation have made it possible to reduce the number of pills by combining their active ingredients into a single gelcap. Single pill combinations were developed with the aim of making it easier for patients to take their daily medications, and simpler for health care professionals to prescribe them.
Single pill combinations can also be the medium for new dosages. Today, such dosages expand health care professionals’ therapeutic treatment options and enable them to address patient needs in the most precise way.
“Current dosages cover a large part of the needs, but some are not yet sufficiently segmented. The unavailability of the right doses necessary to treat a disease like diabetes, for example, forces doctors to ask their patients either to cut their tablet in half or to take two instead of one to obtain the appropriate dose required.”
Emmanuel Arnaud, Global Head of Cardiometabolic and Venous Diseases Therapeutic Area, R&D, Servier
Encouraging therapeutic adherence for more effective treatments
The term therapeutic adherence describes how well a patient follows the medical treatment prescribed by a health care professional and their recommendations. It is conditioned by the patient’s willingness to take charge of their illness and their rational endorsement of the treatment proposed. From this perspective, the patient does not submit to their therapy but rather adheres to it. Adherence is thus manifested by behavior that demonstrates compliance with the treatment and with its prescription over time.
Several studies2,3, 4, 5, 6 have demonstrated the correlation between adherence and therapeutic effectiveness. In other words, the more patients take their treatment correctly, the better they can control their blood pressure, their blood sugar, their cholesterol, or triglyceride levels, etc. In turn, this limits the progression of their disease and the risk of complications.
Preventing serious complications
Managing chronic diseases by opting for the most appropriate treatment helps prevent the onset of serious complications. Diabetes, high blood pressure, and hypercholesterolemia are among the greatest risk factors for cardiovascular diseases and events.7 Heart attack, stroke, peripheral arterial disease (PAD) of the lower extremities, angina pectoris, heart failure, and so forth, cause serious cardiac damage that can have major consequences for the patient and their loved ones, as well as on the cost of health care.
Every year, these chronic diseases are constantly on the rise. Diabetes, and more particularly type 2 diabetes, affects 537 million people worldwide today8. This number is expected to increase to 622 million by 20409. Additionally, 1.28 billion people ages 30 to 79 currently suffer from hypertension, a disease that is predicted to affect 1.56 billion people by 202510.
The call for a return to regular medical monitoring
The question of medical monitoring is even more crucial, as many patients are not monitored regularly11. The consequence of a lack of regular monitoring means insufficient treatment adherence and compliance. Up to 50% of patients do not correctly follow the treatment prescribed to them, whether regarding duration and/or number of pills12.
Did you know?
According to several international studies, non-adherence to treatments for diabetes, hypertension, and high blood lipid levels is responsible for at least 200,000 deaths and generates an additional cost of 125 billion euros each year in Europe13. More broadly, non-adherence contributes to 57% of the total avoidable health care-related costs in the world14 Up to 270 billion USD (United States Dollars), corresponding to 4.6% of total health care spending worldwide14 stand to be saved, as experts estimate that increasing the percentage of people whose hypertension is under control globally to 50% would prevent 76 million deaths between 2023 and 2050. 15
About Servier
Servier, a major player in SPCs in cardiology and metabolism
Servier is the first leading global pharmaceutical group in hypertension and the fifth leading pharmaceutical group in cardiology.16 We have made adherence, a key driver for improving the therapeutic effectiveness of treatments to meet patient needs, our mission.
Guided by the needs of patients, we aim to provide innovative therapeutic solutions through the development of treatments targeting chronic diseases such as hypertension, diabetes, dyslipidemia, and heart failure. Our objective is to promote the implementation of best treatment practices and enable optimal patient care, adapted to each person’s profile at every phase of their disease. Single pill combinations, with their novel combinations of active principles and new dosages, are how we meet this objective.
“As a world leader in cardiometabolic diseases, and owing to our patient-centered approach, therapeutic adherence is central to our strategy in cardiovascular diseases, metabolic diseases, and venous diseases. In our view, this is an essential factor in ensuring the effectiveness of treatments and improving clinical outcomes for patients.”
Viviana Cortese, Head of Cardiometabolism & Venous Disease (CMVD) Global Medical & Patient Affairs at Servier
As pioneers in this field, we are particularly active in medicine life cycle management.
“Today, we have five life cycle management projects in development and six projects in the feasibility stage in the fields of cardiovascular diseases and diabetes .17”
Emmanuel Arnaud, Global Head of Cardiometabolic and Venous Diseases Therapeutic Area, R&D, Servier
New real-world evidence studies published show the benefits of single pill combinations for patients, doctors, and society.
How are single pill combinations (SPCs) developed at Servier?
[1] Thoenes M, et al. Cardiol Res Pract. 2012:925046 / https://pubmed.ncbi.nlm.nih.gov/22242212/
[2] 1.Khatib R. et al. Open Heart. 2019 Jul 3,6(2) e000997; https://openheart.bmj.com/content/6/2/e000997
[3] Adherence: Khunti K et al. Diabetes Care. 2017;40(11):1588-1596/ Control: DISCOVER: Gomes MB et al. Diabetes Res Clin Pract. 2019; 151:20-32; https://pubmed.ncbi.nlm.nih.gov/28801474/
[4] Adherence: Olsen MH et al. Lancet. 2016;388(10060):2665-2712 / Control: Mills KT et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979614/
[5] Adherence: Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 013;34:2940–8 IQVIA RWD / Control : .Gitt AK et al. Eur J Prev Cardiol. 2012;19:221–30; https://pubmed.ncbi.nlm.nih.gov/23907142/
[6] ESC Heart Failure guidelines 2021 https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure
[7] N Engl J Med . 2023 Aug 26. Global Cardiovascular Risk Consortium. Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality https://pubmed.ncbi.nlm.nih.gov/37632466/
[8] International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Consulté en juillet 2022. https://www.diabetesatlas.org
[9] World Health Organization sept 2024 – https://www.who.int/news-room/fact-sheets/detail/diabetes
[10] World Health Organization ; Global report on hypertension: the race against a silent killer. September 2023. https://www.who.int/publications/i/item/9789240081062
[11] NCD Risk Factor Collaboration (NCD-RisC). Lancet. 2021 Sep 11;398(10304):957-980. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants
Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men.
https://pubmed.ncbi.nlm.nih.gov/34450083/
[12] PMC The Unmet Challenge of Medication Nonadherence, 2018 -https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045499/
[13] Investing in medication adherence improves health outcomes and health system efficiency: Adherence to medicines for diabetes, hypertension, and hyperlipidaemia [Internet]. 2018 Jun [cited 2022 Nov 7]. (OECD Health Working Papers; vol. 105). Report No.: 105.
Available from: https://www.oecdilibrary.org/social-issues-migration-health/investing-in-medication-adherenceimproves-health-outcomes-and-health-system-efficiency_8178962c-en
[14] Aitken M, Gorokhovich L. Advancing the Responsible Use of Medicines: Applying Levers for Change [Internet]. Rochester, NY; 2012 [cited 2022 Nov 30].
Available from: https://papers.ssrn.com/abstract=2222541
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2222541
[15] WHO global report on hypertension. The race against a silent killer. 2023- https://www.who.int/publications/i/item/9789240081062
[16] IQVIA, Analytics Link / World 84 countries – MAT Q3-2025
[17] Pipeline as of February 2026